PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
144.3K views | +123 today
Follow

Five Ways Pharma Can Benefit From Digital Health Technologies

From insights.samsung.com

Healthcare has been understandably late to the widespread adoption of digital technology. Extremely restrictive regulations, the presence of multiple key stakeholders, a slow-to-adopt culture and other challenges distinguish healthcare from the retail and finance sectors, which have flourished with their implementations of digital technologies. But pharmaceutical companies (pharma) inhabit a unique position, situated between patients, prescribers and payers, allowing them to gain maximum benefits from a wide array of digital offerings.
No comment yet.

Transformation digitale: le tête à queue du CRM

From www.zdnet.fr

L'acquisition récente de LinkedIn, réseau social pour professionnels, par Microsoft, éditeur de solutions collaboratives et de relatio
Bruno Demay's curator insight, July 26, 3:40 AM

La mise en place des stratégies digitales a fait évoluer la place du CRM dans les entreprises.

La poudre aux yeux de la transformation digitale

From www.linkedin.com

    Il était une fois une entreprise qui se posait des questions sur son avenir. Elle se sentait menacée par un monde auquel elle ne comprenait plus grand chose, un monde plein de nouveaux concurrents
Bruno Demay's curator insight, July 26, 4:02 AM

La transformation digitale est un moyen pour développer l'innovation.

Le chief IoT officer, le nouveau profil que les entreprises vont s'arracher

From www.journaldunet.com

Les premiers recrutements sur ces postes complexes, à cheval entre le business et la technologie, auront lieu dans les grands groupes en 2017.
No comment yet.

Microsoft-backed doctors network expands in Europe

From www.pmlive.com

Online networking and collaboration network Among Doctors has launched in the UK and Spain.The Athens-based online physician community is supported by the Microsoft Innovation Center and aims to connect doctors with colleagues across the globe.

No comment yet.

The Secrets Of People Who Manage To Stick To Habit Changes

From www.fastcompany.com

Want to start or keep a new habit? These masters with long-running streaks can show you how.
No comment yet.

Pharma Can't Just Launch Virtual Clinical Trials and Expect Patients to Show Up

From www.mdconnectinc.com

Pfizer made a big splash back in 2011 with its announcement of the first “virtual” clinical trial. This news was significant because, for the first time, patients would have the opportunity to be screened, enroll, and ultimately participate in a trial entirely via internet-connected devices — in other words, without setting foot on a clinical trial site. In an expensive industry where increased efficiency and patient convenience correlate with profits, this attracted significant (if somewhat skeptical) attention.

 

Some of that skepticism was warranted. According to Michal Orri, Senior Director of Clinical Sciences at Pfizer, the trial initially failed to recruit enough patients. Was this virtual, patient-centered approach a failed model? Hardly: despite the imperfect outcome of this first trial, the Pfizer study has ignited intense interest in virtualization. Today, virtual trials are increasingly common and may, in fact, revolutionize the Pharma industry.

 

Pfizer believes that their initial trial was unsuccessful, incidentally, because it didn’t cater enough to patients. As Outsourcing-Pharma notes, their online process was overly complicated and confusing from the outset. However, after simplifying online enrollment and adding a patient-oriented call center, the trial made appreciable enrollment gains. In fact, the FDA has since requested that they validate their final procedures for more widespread adoption.

 

The essential advantage of virtual trials is that they enable patients to enroll on their own terms; mobile health, e-platforms, remote monitoring devices, wearable technology, and telemedicine all make it simpler, and more inviting, for patients to consent to and participate in trials.

 

Clinical sponsors and CROs will have to employ digital strategies with a measured approach, ensuring that these strategies meet rigorous thresholds for cost-efficiency and usefulness. Even so, most clinical researchers are cautiously optimistic, because such tech tends to allay the skepticism of the most important group of all — the patients.

Pharma Guy's curator insight, July 18, 12:45 PM

Even among clinical cancer studies, as many as 50% of trials never enroll a single patient, according to a 2009 study. But it’s often an issue of education; roughly 85% of cancer patients aren’t aware that clinical treatment is even an option, says the NCBI.

 

Craig Lipset, Head of Clinical Innovation at Pfizer, explained it this way (see here): "I think some of the staunch advocates for using online and social media for recruitment are still reticent to claim silver bullet status and not use conventional channels in parallel. In terms of health literacy, the patient population is largely unaware of clinical trials and participation. You’re going in at a level where there’s still a lot of basic learning needed for individuals to make informed decisions about whether to participate. And doing that without an interaction with a healthcare provider is a challenge."

Pfizer et IBM s'associent contre la maladie de Parkinson

From www.journaldunet.com

La science a recours à l'IoT pour faire une avancée considérable dans la recherche contre les maladies dégénératives
No comment yet.

Apple Scores GlaxoSmithKline Study in Key Test of Health Apps

From www.bloomberg.com

GlaxoSmithKline Plc has started a rheumatoid arthritis study using Apple Inc.’s ResearchKit, marking the first time a drugmaker has used the health system for the iPhone to conduct clinical research.

Glaxo wants to record the mobility of 300 participants over three months and will also ask the patients to input both physical and emotional symptoms, such as pain and mood. The app Glaxo created from ResearchKit comes with a guided wrist exercise that uses the phone’s sensors to record motion, giving the drugmaker a standardized measurement across all users. The company will use the results to help design better clinical trials.

The success of the study could help determine the pharmaceutical industry’s future appetite for using Apple’s products to conduct research. Drugmakers have to balance the lower costs of using the app with their ability to gather accurate, reliable data. Risks include that test subjects will tire of entering information into the app, and, given the iPhone’s $399 starting price, the sample may be skewed toward wealthier demographics.

 

No comment yet.

Merial lance l’application FleaTickRisk 

From www.mypharma-editions.com

Merial, la division santé animale du groupe Sanofi, vient de lancer l’application FleaTickRisk qui évalue en temps réel par localisations géographiques les risques d’infestation ou de piqûre par les puces, les tiques, et certains insectes volants tels les moustiques et les moucherons piqueurs (phlébotomes).
No comment yet.

Want to Do Corporate Innovation Right? Go Inside Google Brain

From hbr.org

Apple fuses technology with design. IBM invests in research that is often a decade ahead of its time. Facebook “moves fast and maintains a stable infrastructure” .Each of these companies, in its own way, is a superior innovator. But what makes Google (now officially known as Alphabet) different is that it doesn’t rely on any one innovation strategy, but deploys a number of them to create an intricate — but powerful — innovation ecosystem that seems to roll out innovations by the dozens. A look at their machine learning team.

No comment yet.

Why do people resist new technologies? History might provide the answer

From www.weforum.org

The same debates we’re having today about new technologies were being had over inventions such as the printed word or cellphones, argues Calestous Juma.Innovation and Its Enemies shows that resistance to new technologies is heightened when the public perceives that the benefits of new technologies will only accrue to a small section of society, while the risks are likely to be widespread. This is why technologies promoted by large corporations often face stiff opposition from the public.

No comment yet.

GlaxoSmithKline targets arthritis in first ResearchKit study by a drug company

From appleinsider.com

Apple's ResearchKit was quickly adopted by clinical studies at a series of universities and hospitals, but a new iOS app focused on rheumatoid arthritis from pharmaceutical firm GlaxoSmithKline marks the first time a drug company has made use of the framework.
VidyaSury's curator insight, July 17, 1:33 AM
Very happy to hear this! arthritis is debilitating.

How AstraZeneca Plans to Bring Medical Meetings to Everyone via Social Media

From azhealthconnections.com

For decades, medical meetings have been a place for doctors, patients, researchers and advocates to engage with each other and share information about the latest advances in treatments and science.

 

That engagement level has exploded over the last few years, however, with the rise of social media. Now, attendees can talk not only to others in the meeting hall but also in every corner of the globe.

 

How important has social media grown to become at medical meetings? Consider: The 2013 American Society of Clinical Oncology (ASCO) Annual Meeting saw 4,352 different people tweet 21,861 times using the #ASCO13 hashtag throughout the year. Two years later, the #ASCO15 meeting was mentioned in 81,273 tweets from 16,664 people – a nearly four-fold increase.

 

AstraZeneca once again will participate in major meetings in our therapeutic areas this year, including ASCO, AHA, ACC, ADA and several others. In addition to our live presence at the meetings, we hope to accomplish the following through our social engagement:

 

Conduct live, authentic dialogue with those in attendance as well as those following along virtually.Share our messages and resources with an informed, engaged audience.Continue conversations begun face to face in the meeting halls.Glean key areas of focus of those affected by the diseases being studied to better inform our efforts as a company.

 

It is increasingly crucial for all players in healthcare to be engaged in social media, as more and more Americans use these platforms.

Pharma Guy's curator insight, June 28, 7:15 AM

Astrazeneca has been a pioneer in hosting authentic Twitter chats. read, for example, “OMG! AstraZeneca Hosts Twitter Chat & World Does NOT End!”; http://bit.ly/AZpharmachat

7 chiffres qui montrent que le digital est vecteur de progrès

From www.frenchweb.fr

Au-delà des 2 100 milliards de dollars de revenus générés par le digital en 2030, ce dernier devrait permettre de diminuer la consommation de pétrole ainsi que les émissions de CO2, selon un rapport GeSI et Accenture.
No comment yet.

La culture digitale en images

From fr.slideshare.net

Visuels issus de nos travaux sur la transformation digitale
Quentin Rst's curator insight, June 29, 12:07 PM
Share your insight
François Pellerin's curator insight, July 10, 1:32 PM

Et son impact sur nos organisations

Jean-Marc Robinet's curator insight, July 10, 3:14 PM
Pour illustrer la culture digitale, rien ne vaut quelques bons visuels plutôt que de longs discours.

Comprendre les Biosimilaires en 3 minutes #hcsmeufr #biosimilaires

From www.youtube.com

Depuis le lancement du premier médicament biosimilaire en Europe en 2006 et suite à l’expiration de brevets de nombreux biomédicaments, le développement de
No comment yet.

Patient-First Marketing: Understanding the Anatomy of a Successful Strategy

From www.slideshare.net

Many healthcare marketers are struggling to find ways to adapt to industry changes and new regulations, and reach their audience effectively. This can be accom…
No comment yet.

What does the sales rep of the future look like?

From mattermark.com

The next-gen sales rep won't be a robot. It'll be a human who understands data and knows how to do one important thing better than anything else.
No comment yet.

Why digital transformation should be a strategic priority for health insurers | McKinsey & Company

From www.mckinsey.com

Digital technologies and applications have the potential to markedly enhance a payor’s profits. Leadership from the top is necessary to overcome the organizational resistance to change that can make a digital transformation difficult.
umanlife's curator insight, June 27, 5:46 AM

Why digital transformation should be a strategic priority for health insurers | McKinsey & Company

Transformation digitale : la culture d’entreprise doit elle aussi évoluer - HBR

From www.hbrfrance.fr

Une culture d’entreprise peut-elle être un frein à la transformation digitale? Une chose est sûre : transformation digitale et culture d’entreprise doivent évoluer de concert pour que ce soit réellement bénéfique pour l’entreprise. La transformation digitale est un sujet à l’agenda des dirigeants de beaucoup d’organisations depuis quelques années. Il …
No comment yet.

Hackathon, agilité, expérimentation, data… les ingrédients de l'entreprise numérique

From www.zdnet.fr

Connaître la technologie ne suffit pas. Et nombre d'entreprises, dont Voyages-SNCF.com, expérimentent ainsi de nouveaux modes d
No comment yet.

Pharmaceutical Companies with the Most "New Chemical Entity" Drugs

From www.drugpatentwatch.com

Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs.

This is one of the longest exclusivity terms provided by the FDA. Only orphan drugs receive a longer term of exclusivity, although the five years granted under the Generating Antibiotic Incentives Now (GAIN) Act may be added in addition to other exclusivities, giving it an effetively longer span.

This chart shows the companies which have received the most new chemical entity exclusivities in the past five years.

No comment yet.